When exposed to IFN-γ, tumor cells additionally exhibit the expression of the immunosuppressive ligand PD-L1, enabling the blockage of the PD-L1/PD-1 interaction as a strategy to harness the immune-mediated responses elicited by trastuzumab. This evidence concerns the gene PDCD1 and neoplasm.